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reatment of Acute Myocardial Infarction
y Hepatocyte Growth Factor Gene Transfer
he First Demonstration of Myocardial Transfer of
“Functional” Gene Using Ultrasonic Microbubble Destruction
sao Kondo, MD, PHD, Koji Ohmori, MD, PHD, Akira Oshita, MD, PHD, Hiroto Takeuchi, MD, PHD,
achiko Fuke, DVM, MCS, Kaori Shinomiya, MD, PHD, Takahisa Noma, MD, PHD,
sunetatsu Namba, MD, PHD, Masakazu Kohno, MD, PHD
agawa, Japan
OBJECTIVES We examined whether ultrasonic microbubble destruction (US/MB) enables therapeutic
myocardial gene transfer of hepatocyte growth factor (HGF) for acute myocardial infarction
(MI).
BACKGROUND Hepatocyte growth factor gene transfer provides cardioprotective effects in MI, which
requires direct intramyocardial injection or special vectors. Although US/MB was used in
myocardial gene transfer, its feasibility in transfer of a therapeutic gene with non-viral vector
remains unknown.
METHODS In a rat model of acute MI, naked plasmid (pVax1) encoding human HGF (1,500 g) was
infused into the left ventricular (LV) chamber during US/MB (HGF-US/MB) or insonation
only (HGF-US) or alone (HGF-alone), while control MI rats received empty pVax1 during
US/MB (pVax1-US/MB). For US/MB, transthoracic intermittent insonation with a diag-
nostic transducer (1.3 MHz) was performed for 2 min at a peak negative pressure of 2,160
kPa during intravenous 20% Optison.
RESULTS Baseline risk area was comparable among the groups. Immunohistology seven days after
treatment revealed significant myocardial expression of HGF protein only in HGF-US/MB.
At three weeks, LV weight in HGF-US/MB (0.89  0.03 g) was significantly lower than
those in HGF-alone (1.09  0.08 g), HGF-US (1.04  0.07 g), and pVax1-US/MB (1.04
 0.05 g). Moreover, scar size was significantly smaller (16 6% vs. 39 5%, 41 6%, and
40  4% of total myocardial circumferential length, respectively), while capillary density (49
 8 vs. 34  5, 37  6, and 36  4 capillaries/high-power field, respectively) and arterial
density (37  7 vs. 15  9, 18  4, and 14  11 arterioles/high-power field, respectively)
in the risk area were higher in HGF-US/MB than the other groups.
CONCLUSIONS Ultrasound-mediated microbubble destruction may enable myocardial HGF gene transfer
with systemic administration of naked plasmid, which enhances angiogenesis, limits infarc-
tion size, and prevents LV remodeling after MI. (J Am Coll Cardiol 2004;44:644–53)
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ocute myocardial infarction (MI) leads to left ventricular
LV) remodeling, including expansion or aneurysm forma-
ion due to cardiomyocyte death in infarcted regions and LV
ilation associated with hypertrophy and fibrosis of non-
nfarcted regions (1).
Hepatocyte growth factor (HGF) exhibits pleiotropic
ffects on various cells (2). Previous studies have demon-
trated that c-Met/HGF receptor is expressed also in
ardiomyocytes and that HGF prevents myocyte death due
o oxidative stress (3) and cardiomyocyte apoptosis during
eperfusion (4). Hepatocyte growth factor gene transfection
efore myocardial ischemia attenuates reperfusion injury
5), while the transfection by direct intramyocardial injec-
ion immediately after coronary ligation induces angiogen-
From the Second Department of Internal Medicine, Kagawa University School of
edicine, Kagawa, Japan.
Manuscript received December 25, 2002; revised manuscript received April 12,004, accepted April 20, 2004.sis in infarcted myocardium (6). Thus, HGF gene therapy
ay be applicable to the treatment of MI.
Adenoviral vectors were used in gene delivery (7,8)
ecause the transfection efficiency is high. However, unfa-
orable immune responses of the host (9) have promoted the
evelopment of non-viral gene delivery techniques. Al-
hough a direct injection of naked plasmid DNA may be a
olution (10–14), the direct injection into the myocardium
equires surgical procedures (13) or catheter-based endo-
yocardial approaches (14).
Recently, ultrasound-induced microbubble destruction
US/MB) has been proposed as a new technique for
ite-specific gene delivery (15–22). Microbubbles (MBs)
urrently used as ultrasound (US) contrast agents can lower
he energy threshold of US for cavitation, which transiently
erforates the cell membrane (18,19) or disrupts the capil-
ary wall to allow delivery of bioactive agents into cells (18)
r interstitial space (15,16). In this regard, US/MB has been
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August 4, 2004:644–53 HGF-Gene Transfer by Ultrasound/Microbubble in MIhown to enhance the adenovirus-mediated myocardial
ransfection of a reporter gene (17,22) with transthoracic
nsonation. However, the transfer of a functional gene to the
yocardium with a naked plasmid in combination with
S/MB has not been demonstrated. Therefore, we tested
he hypothesis that myocardial-targeted disruption of MBs
y transthoracic insonation may enable myocardial gene
ransfer of HGF encoded in a naked plasmid that is infused
nto the circulating blood pool to ameliorate the pathology
n acute MI in rats.
ETHODS
aked HGF plasmid. We used a naked HGF plasmid
AnGes MG Inc., Tokyo, Japan), in which human HGF
omplementary DNA (2.2 kb) was inserted into a eucaryotic
xpression plasmid pVax1 (Invitrogen, Tokyo, Japan) that
tilizes the cytomegalovirus promoter/enhancer (11). The
ector pVax1 that did not contain HGF complementary
NA was used as a control plasmid.
nimal preparation. The study protocol was approved by
he animal research committee of our institution. A total of
8 male Sprague-Dawley rats (250 to 300 g) were anesthe-
ized with an intraperitoneal injection of sodium pentobar-
ital (65 mg/kg). A polyethylene catheter (PE10) was
dvanced into LV through the right external carotid artery
or plasmid injection. The left femoral artery and vein were
annulated for blood pressure and heart rate measurements
igure 1. Protocol of this study. Various treatments following myocardial
ontrast echocardiography (MCE) were performed within 2 h after the
nset of myocardial infarction (MI). Half of the rats in each group were
illed on day 7 for myocardial hepatocyte growth factor (HGF) immuno-
tain. The rest of the rats underwent serial echocardiography until week 3,
hen they were subjected to cardiac catheterization and were killed for
Abbreviations and Acronyms
HGF  hepatocyte growth factor
LV  left ventricle/ventricular
MB  microbubble
MCE  myocardial contrast echocardiography
MI  myocardial infarction
US  ultrasound
US/MB  ultrasound-mediated microbubble destructionTistopathologic assessments.nd for MB infusion, respectively. The animals were ven-
ilated with room air using a respirator SN-480-7 (Shinano,
okyo, Japan). A left lateral thoracotomy was performed at
he fourth intercostal space. The left coronary artery was
ompletely ligated 2 mm distal to its origin from the aorta
sing a 4.0 silk ligature. After the removal of air in the chest,
he incision was closed by sutures. The subsequent proce-
ures in our protocol are shown in Figure 1.
etermination of myocardial risk area during coronary
cclusion. Myocardial contrast echocardiography (MCE)
as performed using a broadband (5 to 12 MHz) transducer
12 of SONOS 5500 (Philips Medical Systems, Andover,
assachusetts) and 10% Optison (Tyco Health Care/
allinckrodt Inc., St. Louis, Missouri), which was intrave-
ously infused at 0.2 ml/min by a syringe pump up to a total
aximal dose of 0.6 ml. Short-axis images of the LV at the
id-papillary muscle level were obtained in the fundamen-
al mode, which provided quantitative myocardial opacifi-
ation in rats (23), with a mechanical index of 1.1 triggering
t every 4th end-systole (Fig. 2A), which were recorded on
O disks. The size of the risk area was expressed as a
ercentage of the myocardial area exhibiting an opacifica-
ion defect in the total LV myocardial area.
GF gene transfer with ultrasonic microbubble destruc-
ion. After MCE, the rats were assorted into four treat-
ent groups as follows: HGF plasmid administration in
ombination with US/MB (HGF-US/MB) (n  16),
ontrol vector administration in combination with US/MB
pVax1-US/MB) (n  13), HGF plasmid administration
ith ultrasound alone (HGF-US) (n  12), and HGF
lasmid infusion only (HGF-alone) (n  15). The treat-
ents were performed within 2 h after coronary ligation. A
otal of 20% Optison was infused via the femoral vein at 0.2
l/min for 5 min. One min after the initiation of MB
nfusion, HGF plasmid (1,500 g) or control pVax1 plas-
id (1,500 g) was infused into the blood pool via LV
atheter for 1.5 min at 1 ml/min. Simultaneously, with the
lasmid infusion, insonation was started with an S3 trans-
ucer of SONOS 5500 (Philips Medical Systems) operating
n ultraharmonic mode (transmit 1.3 MHz/receive 3.6
Hz), which was continued for 4 min. Ultrasound of a
eak negative pressure of 2,160 kPa was transmitted as a
urst of three frames at 28 Hz triggered at every 8th
nd-systole with the focus in the center of LV cavity (Fig.
B). Each burst eliminated all MBs visible in the myocar-
ium, and pulsing-interval of eight cardiac cycles allowed
omplete replenishment of MBs before the next burst (17).
n the HGF-US, insonation was performed in the same
anner for 4 min during intravenous infusion of saline
nstead of 20% Optison. No insonation was performed in
he HGF-alone group during intravenous infusion of saline
or Optison. Thus, all rats excepting those in the HGF-
lone group were exposed to the same insonation, and all
ats received 2.5 ml of fluid in 5 min during the treatments.
o prevent congestive heart failure due to volume overload,
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HGF-Gene Transfer by Ultrasound/Microbubble in MI August 4, 2004:644–53urosemide (0.4 mg/kg) was intramuscularly injected before
he treatments in all rats.
ssessment of LV remodeling and functional reserve.
ransthoracic echocardiographic studies were performed
ith the S12 transducer every week after the treatments to
valuate serial changes in LV dimensions and wall thick-
ess. After the final echocardiographic studies at three
eeks after the treatments, LV pressure was measured with
n ultraminiature transducer SPR-671 (Millar Instruments,
nc., Houston, Texas) via the right common carotid artery.
he peak positive and negative values of the first derivative
f LV pressure (Max-dP/dt, Min-dP/dt) and developed
ressure as the difference in peak systolic and end-diastolic
ressures before and during isoproterenol (107 mol/l)
nfusion (0.2 ml over 1 min) were derived. After the
emodynamic studies, adequate anesthesia was achieved,
nd the heart was removed. After LV weight measurement,
he LV was sliced at the short axis in 3 mm thickness. A part
f the LV was frozen at 80°C, and the rest of the LV was
mmersed in a cold 4% paraformaldehyde solution for 24 h
or Azan-Mallory staining and immunohistochemistry.
istopathologic analyses. One-half of the rats in each
roup were killed at seven days after treatment for determi-
ation of HGF expression by immunohistology. Immuno-
taining of HGF was performed on paraffin-embedded
igure 2. (A) Representative recordings of intermittent short-axis images d
nterval (PI) of every cardiac cycle (PI  1) and of every 4th end systole (PI
uring hepatocyte growth factor gene transfer with ultrasonic microbubblections by using primary antibodies to human HGF (Dako, sarpinteria, California) with a commercial kit (Nitirei,
okyo, Japan). Endogenous peroxidase was inactivated by
reatment with 3% H2O2 in 0.01 M phosphate-buffered
aline (pH 7.4) for 15 min. Any non-specific immunoreac-
ivity was inhibited by pre-incubation with 1% bovine serum
lbumin, phosphate-buffered saline, and 0.1% Tween 20.
ntibody against HGF was placed on the slides and was
ncubated for 24 h. The slides were washed and stained with
,3-diaminobenzidine (Nitirei, Tokyo, Japan). The mag-
itude of HGF expression was semi-quantitated by a
coring system: 0  absent; 1  patchy; 2  homogeneous
tain. Reproducibility of the score was assessed in randomly
elected 10 slides each of which yielded two scores, one for
he marginal viable segment and the other for the remote
ontrol region. The Kappa statistics (24) indicated that the
ntra- and inter-observer agreements were good (kappa 
.68 and 0.63, respectively).
The remaining rats that underwent serial echocardio-
raphic examinations and cardiac catheterization were sub-
ected to histopathology at three weeks after MI. Azan-
allory stain was used to determine the scar corresponding
o infarction, which was quantitated as a percentage of the
car length to the total circumferential length of the LV
yocardial mid-wall at the mid-ventricular level. Angio-
enesis was assessed using endothelial alkaline phosphatase
myocardial contrast echocardiography after coronary occlusion at pulsing
. Arrows denote the risk area. (B) The first frame of the three-frame burst
ruction is shown (top) with an illustration (bottom).uring
 4)
e desttaining (25). Arteriogenesis was assessed with immunohis-
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August 4, 2004:644–53 HGF-Gene Transfer by Ultrasound/Microbubble in MIochemical staining with HHF-35 (Dako), a murine mono-
lonal antibody against endogenous -smooth muscle actin
11,25), which stained primarily medium and large arteries
25). Capillary density and small arterial density (diameter
100 m) were quantitated by counting the vessel number
er high-power field.
Hepatocyte growth factor expression and angiogenesis
ere evaluated in the viable regions adjacent to the scar and
n the remote control areas. At least three portions per
egion were analyzed for each heart. The observers were
linded to the identification of the specimens.
tatistical analysis. All data are expressed as mean  SD.
ifferences in mortality rates among the treatment groups
ere assessed by chi-square test, while those at specific
tages between groups were assessed by one-way analysis of
ariance (ANOVA) with Bonferroni’s correction. One-way
epeated measures of ANOVA with Bonferroni’s correction
ere used in testing serial changes. Changes in the param-
ters by isoproterenol were assessed by paired Student t test.
ifferences were considered significant at p 0.05 after the
orrection for comparisons between HGF-US/MB versus
igure 3. Immunohistology for hepatocyte growth factor (HGF) at 400
car (top) and that obtained from the remote control posterior region (b
icrobubble destruction (US/MB) (HGF-US/MB) exhibited positive stai
ontrol plasmid infusion with US/MB (pVax1-US/MB) and was limite
HGF-US) and naked HGF plasmid infusion without US/MB (HGF-alo
xpression among the groups for the regions adjacent to the scar (B) and
GF-US, and HGF-alone.ach of the other three groups. sESULTS
ifty-six of 68 rats survived after the onset of MI and MCE
nd were subjected to the various treatments. Although
even rats died during or immediately after the treatments,
o rats died subsequently until the final evaluation at three
eeks, except 24 rats that were sacrificed on day 7 for HGF
mmunostaining. There was no difference in the mortality
ate in the four groups by day 7: 12.5% (2 of 16) in
GF-US/MB, 8% (1 of 13) in pVax1-US/MB, 8% (1 of
2) in HGF-US, and 20% (3 of 15) in HGF-alone.
oreover, no significant difference was noted between the
ats that received HGF plasmid (6 of 43  14.0%) and
hose that did not (1 of 12 8.3%). The size of the risk area
f the survivors was comparable among the four groups: 45
5% in HGF-US/MB, 47  4% in pVax1-US/MB, 46 
% in HGF-US, and 47  6% in HGF-alone.
GF gene transfection by ultrasound microbubble de-
truction. Homogeneous HGF expression in the marginal
egions of the viable area was observed only in HGF-US/
B, while no expression of HGF was observed in pVax1-
S/MB, and a patchy perivascular expression was ob-
nification. (A) Sections obtained from the anterior region adjacent to the
) were shown. Naked HGF plasmid infusion with ultrasound-mediated
of HGF in both regions. Hepatocyte growth factor stain was negative in
perivascular regions in naked plasmid HGF infusion during insonation
both regions. Bar graphs compare the score of the magnitude of HGF
the remote non-infarcted regions (C). *p  0.05 versus pVax1-US/MB,mag
ottom
ning
d to
ne) in
forerved in HGF-US group and in HGF-alone group
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imilar in the remote control areas (Fig. 3A, bottom). The
core for HGF expression was significantly higher in HGF-
able 1. Changes in LV Geometry
Baseline
V end-diastolic diameter (mm)
HGF-US/MB 7.46  0.35
pVax1-US/MB 7.38  0.21
HGF-US 7.40  0.20
HGF-alone 7.43  0.40
V end-systolic diameter (mm)
HGF-US/MB 6.69  0.55
pVax1-US/MB 6.35  0.28
HGF-US 6.44  0.30
HGF-alone 6.47  0.33
VS thickness (mm)
HGF-US/MB 1.58  0.05
pVax1-US/MB 1.57  0.06
HGF-US 1.58  0.05
HGF-alone 1.58  0.05
V posterior wall thickness (mm)
HGF-US/MB 1.61  0.06
pVax1-US/MB 1.59  0.09
HGF-US 1.60  0.08
HGF-alone 1.59  0.08
ractional shortening (%)
HGF-US/MB 10.4  5.0
pVax1-US/MB 12.8  4.2
HGF-US 12.7  3.9
HGF-alone 12.9  4.3
V mass (g)
HGF-US/MB 0.81  0.09
pVax1-US/MB 0.80  0.05
HGF-US 0.81  006
HGF-alone 0.81  0.08
p  0.05 versus pVax1-US/MB; †p  0.05 versus HGF-alone; ‡p  0.05 versus H
HGF-alone  naked HGF plasmid infusion without US/MB (n  6); HGF-US
GF plasmid infusion with US/MB (n  7); IVS  intraventricular septum; LV 
ultrasound-mediated microbubble destruction.
igure 4. Representative recordings of left ventricular (LV) two-dimensi
reatments. Left ventricular remodeling was almost completely inhibited
ltrasound-mediated microbubble destruction (US/MB) (HGF-US/MB) g
n the other groups. Other abbreviations as in Figure 3.S/MB than in the other groups (all, p 0.05) both for the
arginal regions of viable area (Fig. 3B) and remote control
rea (Fig. 3C).
Week 2 Weeks 3 Weeks
 0.55*†‡ 8.17  0.59*‡§ 8.26  0.60*
 0.18 8.90  0.23§ 9.22  0.30§
 0.21 8.94  0.21§ 9.32  0.28§
 0.30 9.12  0.55§ 9.68  0.74§
 0.53*†‡ 6.76  0.45*†‡ 6.66  0.47*†‡
 0.19§ 7.92  0.35§ 8.17  0.29§
 0.20§ 7.98  0.35§ 8.22  0.31§
 0.68§ 8.12  0.51§ 8.62  0.74§
 0.12*†‡§ 1.27  0.16*†‡§ 1.27  0.15*†‡§
 0.08§ 1.09  0.10§ 1.08  0.09§
 0.07§ 1.08  0.09§ 1.08  0.09§
 0.07§ 1.08  0.11§ 1.07  0.06§
 0.07 1.59  0.06 1.60  0.08
 0.06 1.59  0.05 1.60  0.08
 0.08 1.59  0.08 1.59  0.08
 0.07 1.58  0.08 1.58  0.10
 7.6 17.1  6.4 19.1  6.9§
 2.3 11.1  1.7 11.4  2.5
 2.8 10.9  2.0 10.9  2.1
 5.3 11.0  2.1 11.0  2.5
 0.09 0.82  0.14*†‡ 0.83  0.11*†‡
 0.06 0.85  0.06§ 0.92  0.07§
 0.07 0.85  0.05§ 0.93  0.08§
 0.04§ 0.89  0.13§ 0.97  0.21§
S; §p  0.05 versus baseline.
ked HGF plasmid infusion with ultrasound only (n  6); HGF-US/MB  naked
tricular; pVax1-US/MB  control plasmid infusion with US/MB (n  6); US/MB
(top) and M-mode (bottom) echocardiography at three weeks after the
rat form naked plasmid hepatocyte growth factor (HGF) infusion with
while the intraventricular septum was thinned and LV chamber was dilated1
7.94
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8.26
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August 4, 2004:644–53 HGF-Gene Transfer by Ultrasound/Microbubble in MIerial changes in LV geometry. Baseline echocardio-
raphic variables for LV geometry and function were similar
mong the groups (Table 1). Progressive increases in LV
imensions and LV mass were observed, and fractional
hortening failed to improve in the pVax1-US/MB, HGF-
S, and HGF-alone groups. However, in the HGF-US/
B, LV end-systolic dimension remained unchanged with
slight increase in end-diastolic dimension, which resulted
n unchanged LV mass and improved fractional shortening
Table 1). Thus, at week 3, substantial improvements of LV
eometry and function were achieved only in HGF-US/MB
s shown in Figure 4, while intraventircular septum was
hinned and LV chamber was dilated in the other groups.
eft ventricular tissue weight was significantly lower in
GF-US/MB (0.89  0.03 g) than in pVax1-US/MB
1.04 0.05 g), HGF-US (1.04 0.07 g), and HGF-alone
1.09  0.08 g) (all, p  0.05) at week 3. Thus, LV
emodeling after MI was successfully prevented only in
GF-US/MB.
eserve for inotropic stimulation. The baseline (pre-
soproterenol) heart rate and systolic blood pressure at week
were similar among the four groups (Table 2). Developed
ressure was significantly higher in HGF-US/MB than that
n the other groups due to lower LV end-diastolic pressure.
he max-dP/dt and min-dP/dt at baseline were greater in
GF-US/MB than those in the other three groups. Al-
hough all values increased in response to isoproterenol in
GF-US/MB, only heart rate responded in the other
roups (Table 2). Thus, the reserve for inotropic stimulation
as preserved only in HGF-US/MB group.
xtent of scar formation. A large scar in the anterior wall
as observed on Azan-Mallory-stained sections in a rat
rom the pVax1-US/MB group (Fig. 5B) and in rats from
GF-US (Fig. 5C) and from HGF-alone (Fig. 5D). In
ontrast, the scar was much smaller in a rat of HGF-
S/MB (Fig. 5A). Thus, scar size was significantly smaller
able 2. Hemodynamic Responses to Isoproterenol Infusion
HGF-US/MB
ystolic pressure (mm Hg)
Baseline 127  16
Isoproterenol 146  12†§
eveloped pressure (mm Hg)
Baseline 120  16*†‡
Isoproterenol 142  12*†‡§
eart rate (beats/min)
Baseline 385  16
Isoproterenol 410  17§
ax-dP/dt (mm Hg/s)
Baseline 7,699  944*†‡
Isoproterenol 11,943  2,839*†‡§
in-dP/dt (mm Hg/s)
Baseline 5,113  626*†‡
Isoproterenol 5,914  1,084*†‡
p  0.05 versus pVax1-US/MB; †p  0.05 versus HGF-alone; ‡p  0.05 versus H
Max-dP/dt  maximum first derivative of left ventricular pressure; Min-dP/dt 
ats for each group as in Table 1.n HGF-US/MB (16  6% of total myocardial mid-wall Aength) than in pVax1-US/MB (39 5%), HGF-US (41
%), and HGF-alone (40  4%) (all, p  0.05).
apillary and artery density. Increase in capillaries in the
yocardium adjacent to the infarcted area was observed in
rat from HGF-US/MB as compared with those from the
ther groups (Fig. 6A, top). Such a difference was not
bserved in the non-infarcted remote regions (Fig. 6A,
ottom). The capillary density in the region adjacent to the
nfarction was 1.5-fold higher in HGF-US/MB than that in
he other groups (all, p  0.05) (Fig. 6B), although the
ensity in non-infarcted regions was comparable among the
our groups (Fig. 6C).
A significant increase in arterial count was noted in the
egion adjacent to the infarcted region in a rat from
GF-US/MB group, compared with that in rats in the
pVax1-US/MB HGF-US HGF-alone
115  17 120  11 119  15
117  16 126  18 128  22
100  14 106  12 101  16
99  15 111  18 109  27
388  17 386  14 391  17
411  9§ 418  16§ 415  13§
4,958  745 5,021  680 4,537  900
7,120  889 6,904  902 5,567  1,499
3,715  701 4,012  401 3,858  353
3,812  311 3,942  561 3,551  539
S; §p  0.05 versus baseline.
mum first derivative of left ventricular pressure. Other abbreviations and number of
igure 5. Azan-Mallory stain (100 magnification). Scar corresponding
o the infarction was small in a rat from HGF-US/MB (A) compared with
hose from pVax1-US/MB (B), HGF-US (C), and from HGF-alone (D).GF-U
minibbreviations as in Figure 3.
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n the non-infarcted remote regions (Fig. 7A, bottom). The
umber of small arteries was threefold higher in the region
djacent to the infarcted area in HGF-US/MB group than
hat in the other three groups (Fig. 7B) although that in the
on-infarcted regions was comparable among the four
roups (Fig. 7C). Thus, angiogenesis and arteriogenesis
ere enhanced in the border zone adjacent to the infarction
nly in the HGF-US/MB group.
ISCUSSION
his report describes the first successful therapeutic gene
elivery to the heart by means of US/MB. The naked
lasmid encoding HGF that was infused into the blood pool
ia the LV chamber was successfully delivered to the
yocardium by insonation during intravenous MB infusion.
epatocyte growth factor gene delivery with this method in
he acute phase of experimental MI successfully prevented
ubsequent scar formation and LV remodeling.
GF gene transfer with ultrasonic microbubble destruc-
ion. Intravital microscopic observations have demon-
trated that US disrupts MBs in capillaries, which results in
apillary rupture (15,16). In this way, intravenously injected
olymer microspheres could be driven as much as 200 m
igure 6. Endothelial alkaline phosphatase stain (400 magnification). (A
n a rat from HGF-US/MB than those from other groups (top). No sign
emote non-infarcted regions (bottom). Bar graphs compare the vessel co
he scar (B) and for the remote non-infarcted regions (C). *p  0.05 versnto the parenchyma (15), which provided the basis for AS/MB-mediated microinjection of bioactive agents into
issues through the barrier of vessel wall. In this regard,
everal investigators have demonstrated that US/MB en-
bles delivery of genes (17–22) to specific tissues, including
he myocardium (17,22). Thus, US/MB has been shown to
nhance the transfer of endothelial nitric oxide synthase
ene using a naked plasmid to the swine coronary artery in
itro (21) and the ex vivo transfection of anti-oncogene p-53
lasmid to the rat carotid artery (20). More recently,
S/MB has been used to enhance the delivery of HGF into
he skeletal muscle by direct intramuscular injection of a
aked plasmid into the rat hind limbs (19). This technique
as applied to the heart, and the successful cardiac delivery
f a reporter gene expressing -galactosidase was achieved
y using an adenovirus vector loaded on MBs (17). How-
ver, for the therapeutic use in patients, innovations in less
nvasive non-viral plasmid DNA-based gene transfer with
igh transfection efficiency would be desirable. In this study,
hen US/MB was combined, naked HGF plasmid injected
nto the blood pool in the LV chamber, not the direct
njection or intracoronary injection, was successfully trans-
erred into the myocardium as evidenced by significant
xpression of HGF protein at day 7, which was related to
he limited infarct size and subsequent LV remodeling.
the regions adjacent to the scar, capillary density was significantly higher
t differences were noted among the groups in the capillary density in the
er high-power field (HPF) among the groups for the regions adjacent to
ax1-US/MB, HGF-US, and HGF-alone. Abbreviations as in Figure 3.) In
ifican
unt p
us pVlthough a relatively high dose of the plasmid could be
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August 4, 2004:644–53 HGF-Gene Transfer by Ultrasound/Microbubble in MIeeded for intravenous injection to achieve the similar
lasmid concentration obtainable with intra-LV chamber
njection, the present results provide the basis for the
pplication of US/MB for non-viral transfection of thera-
eutic genes into the myocardium by systemic administra-
ion of the naked plasmid.
Insonation with such a low-frequency and high mechan-
cal index as employed in this study may increase the
ermeability of endothelium even in the absence of MBs
specially in application in rats offering less ultrasound
ttenuation, which may enhance the transfection of plas-
ids. However, no significant enhancement of the trans-
ection was achieved in the HGF-US group in our rat
odel. In a previous study, similar insonation condition
frequency of 1.8 MHz, mechanical index of 1.6) induced
nly a limited microvascular rupture in the rabbit hearts
uspended in a buffer solution in the absence of MBs (26).
herefore, a greater disruption may be needed in the naked
lasmid transfection, and the combination of microbubble
nfusion and insonation seems to be necessary for the future
pplication to humans in which a greater attenuation is
xpected. On the other hand, as assessed with HGF
xpression, transfection of HGF plasmid was enhanced by
S/MB also in the remote control regions located in the LV
igure 7. Anti--smooth muscle actin immuno-stain (100 magnification).
emonstrated only in a rat from HGF-US/MB but not in the other groups (top
bottom). Bar graphs compare the count of vessels per high-power field (HP
emote non-infarcted regions (C). *p  0.05 versus pVax1-US/MB, HGF-Uosterior wall where ultrasound would possibly be attenu- Hted. Therefore, bioeffects of US/MB were likely homoge-
eous in the entire short-axis cross-section of LV wall.
Because the coronary artery was completely ligated, no
ntegrade perfusion existed in the risk area. Influx of MBs
nd the plasmid in the risk area are assumed to have been
rovided by the collateral circulation or by the Thebesian
eins directly from LV chamber (27).
No significant increase in ventricular premature beats was
bserved during US/MB, and mortality rate in HGF-
S/MB was similar to those in the other groups. Moreover,
he pVax1-US/MB did not show further deteriorations of
yocardial function or larger infarct size compared with
hose in HGF-alone that did not undergo US/MB. Thus,
dverse effects of US/MB were not observed in the present
tudy. Similarly, mortality rate was not significantly different
etween the rats who received HGF plasmid and those who
eceived pVax-1. Thus, no significant adverse effects of
GF plasmid injection such as abnormal immune stimula-
ion, cytokine activation, or hemodynamic impairment were
bserved in the present study.
ardioprotection by HGF in MI. Higher HGF concen-
ration in the vein collecting the blood from the territory of
nfarct related artery was shown to result in less severe LV
nlargement in patients with reperfused acute MI (28).
n the regions adjacent to the scar, significant increase in arterial density was
ese groups showed similar vascular density in the remote non-infarcted regions
ong the groups for the regions adjacent to the infarction scar (B) and for the
d HGF-alone. Abbreviations as in Figure 3.(A) I
). Th
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HGF-Gene Transfer by Ultrasound/Microbubble in MI August 4, 2004:644–53GF gene to the myocardium in the acute phase of MI may
ttenuate progression of LV dysfunction in the chronic
hase. In the present study, serial echocardiographic obser-
ations revealed that LV remodeling was much less, and LV
unction rather progressively improved in the group of
GF-US/MB. Importantly, the scar corresponding to the
ore of infarction was significantly smaller in this group,
hich resulted in the preserved inotropic reserve for sym-
athetic stimulation by isoproterenol. The effects of HGF
re dependent on its binding to the transmembrane receptor
ncoded by the proto-oncogene, c-Met. In MI, c-Met
xpression was increased in the periphery of the infarcted
egion (29), and the sensitivity to and the effects of HGF are
nhanced in this region, resulting in less cell death (3,4) and
ore angiogenesis (6). Thus, although HGF expression was
nhanced also in the remote control regions in HGF-US/
B, angiogenesis and arteriogenesis were significantly en-
anced only in viable regions surrounding the infarct area
here c-Met/HGF receptor is known to be up-regulated
29).
Besides angiogenesis, the cardiac HGF system also exerts
ytoprotective effects against ischemic injury through its
nti-oxidative (3) and anti-apoptotic (4) effects, which may
lso contribute to salvage of ischemic myocardium. Hepa-
ocyte growth factor stimulates the degradation of extracel-
ular matrix and inhibits its synthesis induced by angiotensin
I (30). Administration of human recombinant HGF pre-
ented and/or regressed fibrosis in the liver (31) and the
ung (32). Human HGF complementary DNA transfection
o the myocardium by means of hemoagglutinating virus of
apan-liposome prevented myocardial fibrosis in an animal
odel developing cardiomyopathy (33). Thus, HGF can
odulate wound-healing processes and prevent scar forma-
ion.
Hepatocyte growth factor expression level relatively early
fter the gene transfer might be sufficient to exert direct
reventive effects on cell death under severe ischemia and/or
ugment the residual vascular function including recruit-
ent of latent collateral vessels to reduce the ischemia. In
he subacute phase, angiogenesis became significant, which
urther improved myocardial ischemia, while anti-fibrotic
ction played a role in preventing scar formation. Decrease
n infarct size can limit subsequent mechanical stress and
eurohumoral stimulation to non-infarcted region resulting
n increased LV mass. All these processes may be integrated
nto the successful prevention of postinfarction remodeling
y HGF gene transfer to the heart at acute phase of MI.
In HGF-US/MB, we observed a 60% reduction in infarct
ize (scar size) compared with those in controls. This was
elatively greater than those seen in previous reports on
nfarct-limiting effects of basic fibroblast growth factor by
5% (34) or with cerivastatin by 49% (35), both of which
ere evaluated in acute phase. Progressive expansion of
nfarct region occurred by three weeks after MI only in the
neffectively treated groups, while it was almost absent in theGF-US/MB group in our study. This may be a reason forhe greater relative reduction of scar size in our effective
reatment group.
tudy limitations. Because the capillaries identified by
lkaline phosphatase stain sometimes formed a continuous
etwork rather than punctate cross-sections in the margins
f viable regions in the HGF-US/MB group, the angiogen-
sis quantitated as the capillary count in this study might be
nderestimated in these regions.
Because we infused the plasmid into the circulating blood
ool, a relatively high dose of HGF plasmid (1,500 g/
ody) was necessary compared with previous studies (20
g/body [19] and 100 to 500 g/body [11]) that employed
he direct intra-tissue injection of the plasmid. To avoid
ossible alterations of acoustic properties of the MB that has
een approved for clinical use in many countries, the
lasmid was not loaded on the shell of MB as in previous
tudies (17,21). The naked plasmid injected into the blood
s easily degraded by DNase or captured by non-specific
cavenger receptors (36), which leads to rapid decrease in
oncentration of the plasmid reaching the target regions.
herefore, we chose to inject the plasmid into the LV
hamber rather than the peripheral vein. Incorporation or
ttachment of the plasmid on the MB shell may overcome
uch limitations. This may enable the local release of
lasmid at the region where US is applied and, thereby,
ould reduce the required dose of plasmid or would enable
ntravenous injection of the plasmid, which was not tested
n this study.
The efficiency of gene transfection by US/MB should be
ependent upon insonation conditions as well as MBs
tructure. Therefore, further studies are necessary to opti-
ize the insonation condition in the specific target organs
ith various acoustic properties in larger animals. Similarly,
ecause capillary disruption is known to occur in the settings
f clinical MCE and presumably underlies the present
esults as the mechanism, future studies should pursue the
radeoff between the efficacy and safety in respect to MB
oncentration and US intensity.
cknowledgments
he authors are grateful to AnGes MG Inc., Tokyo, Japan,
or providing the naked plasmid encoding HGF.
eprint requests and correspondence: Dr. Koji Ohmori, The
econd Department of Internal Medicine, Kagawa University School
f Medicine, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa 761-
793 Japan. E-mail: komori@kms.ac.jp.
EFERENCES
1. McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular
remodeling after myocardial infarction: a corollary to infarct expansion.
Circulation 1986;74:693–702.
2. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as
tissue organizer for organogenesis and regeneration. Biochem Biophys
Res Commun 1997;239:639–44.
3. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura
T. A potential cardioprotective role of hepatocyte growth factor in
myocardial infarction in rats. Cardiovasc Res 2001;51:41–50.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
653JACC Vol. 44, No. 3, 2004 Kondo et al.
August 4, 2004:644–53 HGF-Gene Transfer by Ultrasound/Microbubble in MI4. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H,
Nakamura T. Myocardial protection from ischemia/reperfusion injury
by endogenous and exogenous HGF. J Clin Invest 2000;106:1511–9.
5. Ueda H, Sawa Y, Matsumoto K, et al. Gene transfection of hepatocyte
growth factor attenuates reperfusion injury in the heart. Ann Thorac
Surg 1999;67:1726–31.
6. Aoki M, Morishita R, Taniyama Y, et al. Angiogenesis induced by
hepatocyte growth factor in non-infarcted myocardium and infarcted
myocardium: up-regulation of essential transcription factor for angio-
genesis, etc. Gene Ther 2000;7:417–27.
7. Kass EA, Falck PE, Alvira M, et al. Quantitative determination of
adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and
in vivo. Proc Natl Acad Sci USA 1993;90:11498–502.
8. French BA, Mazur W, Geske RS, et al. Direct in vivo gene transfer
into porcine myocardium using replication-deficient adenoviral vec-
tors. Circulation 1994;90:2414–24.
9. Verma IM, Somia N. Gene therapy: promises, problems and pros-
pects. Nature 1997;389:239–42.
0. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene
transfer of naked DNA encoding vascular endothelial growth factor
augments collateral development and tissue perfusion. Circulation
1996;94:3281–90.
1. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis
induced by human hepatocyte growth factor gene in rat and rabbit
hindlimb ischemia models: preclinical study for treatment of peripheral
arterial disease. Gene Ther 2001;8:181–9.
2. Lin H, Parmacek MS, Morle G, et al. Expression of recombinant
genes in myocardium in vivo after direct injection of DNA. Circula-
tion 1990;82:2217–21.
3. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial
angiogenesis: initial clinical results with direct myocardial injection of
phVEGF165 as sole therapy for myocardial ischemia. Circulation
1998;98:2800–4.
4. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind,
placebo-controlled pilot study of catheter-based myocardial gene
transfer for therapeutic angiogenesis using left ventricular electrome-
chanical mapping in patients with chronic myocardial ischemia.
Circulation 2001;103:2138–43.
5. Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S. Direct in vivo
visualization of intravascular destruction of microbubbles by ultra-
sound and its local effects on tissue. Circulation 1998;98:290–3.
6. Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of colloidal particles
and red blood cells to tissue through microvessel ruptures created by
targeted microbubble destruction with ultrasound. Circulation 1998;
98:1264–7.
7. Shohet RV, Chen S, Zhou YT, et al. Echocardiographic destruction of
albumin microbubbles directs gene delivery to the myocardium.
Circulation 2000;101:2554–6.
8. Lawrie A, Brisken AF, Francis SE, Cumberland DC, Crossman DC,
Newman CM. Microbubble-enhanced ultrasound for vascular gene
delivery. Gene Ther 2000;7:2023–7.
9. Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and
efficient novel nonviral gene transfer using ultrasound: enhancement of
transfection efficiency of naked plasmid DNA in skeletal muscle. Gene
Ther 2002;9:372–80.0. Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid
DNA into rat carotid artery using ultrasound. Circulation 2002;105:
1233–9.
1. Teupe C, Richter S, Fisslthaler B, et al. Vascular gene transfer of
phosphomimetic endothelial nitric oxide synthase (S1177D) using
ultrasound-enhanced destruction of plasmid-loaded microbubbles im-
proves vasoreactivity. Circulation 2002;105:1104–9.
2. Beeri R, Guerrero JL, Supple G, Sullivan S, Levine RA, Hajjar RJ.
New efficient catheter-based system for myocardial gene delivery.
Circulation 2002;106:1756–9.
3. Oshita A, Ohmori K, Yu Y, et al. Myocardial blood flow measure-
ments in rats with simple pulsing contrast echocardiography. Ultra-
sound Med Biol 2002;28:459–66.
4. Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatis-
tics of concordance. Clin Pharmacol Ther 1989;46:309.
5. Hughes GC, Lowe JE, Kypson AP, et al. Neovascularization after
transmyocardial laser revascularization in a model of chronic ischemia.
Ann Thorac Surg 1998;66:2029–36.
6. Ay T, Havaux X, Van Camp G, et al. Destruction of contrast micro-
bubbles by ultrasound: effects on myocardial function, coronary perfusion
pressure, and microvascular integrity. Circulation 2001;104:461–6.
7. Ansari A. Anatomy and clinical significance of ventricular Thebesian
veins. Clin Anat 2001;14:102–10.
8. Yasuda S, Goto Y, Baba T, et al. Enhanced secretion of cardiac
hepatocyte growth factor from an infarct region is associated with less
severe ventricular enlargement and improved cardiac function. J Am
Coll Cardiol 2000;36:115–21.
9. Sato T, Tani Y, Murao S, et al. Focal enhancement of expression of
c-Met/hepatocyte growth factor receptor in the myocardium in human
myocardial infarction. Cardiovasc Pathol 2001;10:235–40.
0. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution
of a novel antifibrotic factor, hepatocyte growth factor, to prevention of
myocardial fibrosis by angiotensin II blockade in cardiomyopathic
hamsters. Circulation 2000;102:246–52.
1. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene
therapy of liver cirrhosis in rats. Nat Med 1999;5:226–30.
2. Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or
delayed administration of hepatocyte growth factor equally represses
the fibrotic changes in murine lung injury induced by bleomycin: a
morphologic study. Am J Respir Crit Care Med 1997;156:1937–44.
3. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifi-
brotic action by hepatocyte growth factor in cardiomyopathy. Hyper-
tension 2002;40:47–53.
4. Horrigan MC, Malycky JL, Ellis SG, et al. Reduction in myocardial
infarct size by basic fibroblast growth factor following coronary
occlusion in a canine model. Int J Cardiol 1999;68 Suppl 1:S85–91.
5. Wolfrum S, Grimm M, Heidbreder M, et al. Acute reduction of
myocardial infarct size by a hydroxymetyl glutaryl coenzyme A
reductase inhibitor is mediated by endothelial nitric oxide synthase.
J Cardiovasc Pharmacol 2003;41:474–80.
6. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after
intravenous injection in mice: involvement of scavenger receptors in its
hepatic uptake. Pharm Res 1995;12:825–30.
